Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

Return to program book search

Session Information

SYM S061 - Melanoma Prevention: It's Time

Open admission to eligible categories, no tuition or ticket


Date: Tuesday, March 05

CME Credits: 3.00

Location: Flamingo 1/2

Time: 2:00 PM - 5:00 PM

Director: Sancy A. Leachman, MD, PhD, FAAD


  • Zalfa Abdel-Malek, PhD - Handout
  • Pamela Cassidy, MD - Handout
  • Robert Paul Dellavalle, MD, PhD, FAAD - Handout
  • James M. Grichnik, MD, PhD, FAAD - Handout
  • Allan C. Halpern, MD, FAAD
  • Joanne Jeter
  • Caroline C. Kim, MD, FAAD
  • Kenneth G. Linden, MD, FAAD
  • Martin A. Weinstock, MD, PhD, FAAD

Learning Objectives:
Following this course, the attendee should be able to:

  • Recognize how a dermatologist can participate in and contribute to melanoma prevention at a local and national level.
  • Compare current prevention and early detection strategies with emerging concepts nationally and worldwide.
  • Assess the prevention potential of the most promising chemoprevention agents for melanoma.

Effective prevention or chemoprevention of melanoma could substantially reduce the societal burden of this disease. Dermatologists are on the front-line of melanoma prevention messaging, early detection, and screening and are poised to make major contributions in national melanoma prevention efforts. In this symposium we will discuss how dermatologists can become involved in National Cancer Cooperative Groups (e.g. SWOG/ECOG), and best contribute to multidisciplinary melanoma care. We will provide a status report on public messaging and screening efforts and describe emerging techniques for earlier detection of melanoma. Finally, we will discuss the most promising compounds for chemoprevention of melanoma.


  • Curiel-Lewandrowski C, Kim CC, Swetter SM, Chen SC, Halpern AC, Kirkwood JM, Leachman SA, Marghoob AA, Ming ME, Grichnik JM; Melanoma Prevention Working Group—Pigmented Skin Lesion Sub-Committee.Survival is not the only valuable end point in melanoma screening. J Invest Dermatol. 2012 May;132(5):1332-7.
  • Duffy K, Grossman D. The dysplastic nevus: From historical perspective to management in the modern era: Part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol. 2012 Jul;67(1):1.e1-1.e16.
  • Katalinic A, Waldmann A, Weinstock MA, Geller AC, Eisemann N, Greinert R, Volkmer B, Breitbart E. Does skin cancer screening save lives?: An observational study comparing trends in melanoma mortality in regions with and without screening. Cancer. 2012 Apr 19.


Tuesday, March 05
2:00 PMThe Melanoma Prevention Working Group: What’s going on Nationally? / Dr. Leachman
2:10 PMThe Pigmented Lesion Subcommittee: How can we integrate Dermatology experience? / Dr. Kim
2:20 PMModernizing the sun safety message in public health / Dr. Dellavalle
2:30 PMIs it time for Americans to be screened: How Germany is doing it / Dr. Weinstock
2:40 PMHow to catch melanoma earlier: subtle changes can be key. / Dr. Grichnik
2:50 PMThe future is now: State-of-the-art early detection / Dr. Halpern
3:00 PMBroccoli sprouts and sulforaphane: Can antioxidants prevent melanoma? / Dr. Leachman
3:10 PMMore than a Tylenol overdose drug: N-acetyl cysteine for melanoma chemoprevention / Cassidy
3:20 PMVitamin D: Is it time for a Southwest Oncology Group Multicenter Trial / Dr. Jeter
3:30 PMBarbie drugs and prevention: The potential and pitfalls of MSH agonists / Abdel-Malek
3:40 PMLovastatin: Results from the first multicenter, prospective, prevention study / Dr. Linden